当前位置: X-MOL 学术J. Biotechnol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Mannosylated chitosan nanoparticles loaded with FliC antigen as a novel vaccine candidate against Brucella melitensis and Brucella abortus infection.
Journal of Biotechnology ( IF 4.1 ) Pub Date : 2020-02-01 , DOI: 10.1016/j.jbiotec.2020.01.016
Zohre Sadeghi 1 , Mahdi Fasihi-Ramandi 2 , Mohammad Azizi 3 , Saeid Bouzari 1
Affiliation  

Brucellosis is a worldwide bacterial zoonosis disease. Live attenuated Brucella vaccines have several drawbacks. Thus development of a safe and effective vaccine for brucellosis is a concern of many scientists. FliC protein contributes in virulence of Brucella; hence, it is a promising target for brucellosis vaccine. In this study, Mannosylated Chitosan Nanoparticles (MCN) loaded with FliC protein were synthesized as a targeted vaccine delivery system. The immunogenicity and protective efficacy of FliC and FliC-MCN against Brucella infection were evaluated in BALB/c mice. After cloning, expression and purification, FliC protein was loaded on MCN. The particle size, loading efficiency and in vitro release of the NPs were determined. Our investigation revealed that FliC and FliC-MCN could significantly increase specific IgG response (higher IgG2a titers). Besides, spleen cells from immunized mice produced high level of IFN-γ and IL-2 and low level IL-10 cytokines. Immunization with FliC and FliC-MCN conferred significant degree of protection against B. melitensis 16 M and B. abortus 544 infections. Overall these results indicate that FliC protein would be a novel potential antigen candidate for the development of a subunit vaccine against B. melitensis and B. abortus. Moreover, MCN could be used as an adjuvant and targeted vaccine delivery system.

中文翻译:

载有FliC抗原的甘露糖基化的壳聚糖纳米颗粒可作为抗布鲁氏菌和流产布鲁氏菌感染的新型候选疫苗。

布鲁氏菌病是一种世界范围的细菌性人畜共患病。减毒的布鲁氏菌活疫苗有几个缺点。因此,开发用于布鲁氏菌病的安全有效的疫苗是许多科学家关注的问题。FliC蛋白有助于布鲁氏菌的致病性;因此,它是布鲁氏菌病疫苗的有希望的靶标。在这项研究中,负载了FliC蛋白的甘露糖基化的壳聚糖纳米颗粒(MCN)被合成为靶向疫苗递送系统。在BALB / c小鼠中评估了FliC和FliC-MCN对布鲁氏菌感染的免疫原性和保护功效。克隆,表达和纯化后,将FliC蛋白加载到MCN上。测定了NP的粒径,负载效率和体外释放。我们的研究表明FliC和FliC-MCN可以显着提高特异性IgG反应(更高的IgG2a滴度)。此外,免疫小鼠的脾细胞产生高水平的IFN-γ和IL-2和低水平的IL-10细胞因子。用FliC和FliC-MCN免疫可显着程度地保护抵抗肉芽孢杆菌16 M和流产芽孢杆菌544感染。总的来说,这些结果表明,FliC蛋白将是开发针对抵抗双歧杆菌和流产双歧杆菌的亚单位疫苗的新型潜在抗原候选物。此外,MCN可用作佐剂和靶向疫苗输送系统。流产544例感染。总的来说,这些结果表明,FliC蛋白将是开发针对抵抗双歧杆菌和流产双歧杆菌的亚单位疫苗的新型潜在抗原候选物。此外,MCN可用作佐剂和靶向疫苗输送系统。流产544例感染。总体而言,这些结果表明,FliC蛋白将是开发针对B. melitensis和B.流产的亚单位疫苗的新型潜在抗原候选物。此外,MCN可用作佐剂和靶向疫苗输送系统。
更新日期:2020-02-01
down
wechat
bug